Recombinant rabies virus with the glycoprotein fused with a DC-binding peptide is an efficacious rabies vaccine
Metrics: PDF 1351 views | HTML 2389 views | ?
Yachun Zhang1,2, Ming Zhou1,2, Yingying Li1,2, Zhaochen Luo1,2, Huanchun Chen1,2, Min Cui1,2, Zhen F. Fu1,2,3 and Ling Zhao1,2
1State Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China
2College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China
3Department of Pathology, University of Georgia, Athens, GA 30602, USA
Ling Zhao, email: [email protected]
Keywords: rabies virus; dendritic cells; DC-binding peptides; rabies vaccine
Received: September 14, 2017 Accepted: November 15, 2017 Published: December 11, 2017
Our previous studies demonstrated that recruiting and/or activating dendritic cells (DCs) enhanced the immunogenicity of recombinant rabies viruses (rRABV). In this study, rRABV LBNSE with a small DC-binding peptide (designated as rLBNSE-DCBp) or a negative control peptide (designated as rLBNSE-DCCp) fused to the glycoprotein (G) was constructed and rescued. As expected, significantly more activated DCs were detected in rLBNSE-DCBp-immunized mice than those immunized with rLBNSE or rLBNSE-DCCp. Subsequently, significantly more generation of TFH and GC B cells were observed in rLBNSE-DCBp immunized mice than those in rLBNSE or rLBNSE-DCCp-immunized mice. In addition, significantly higher levels of virus neutralizing antibodies (VNAs) were observed in mice immunized with rLBNSE-DCBp than those immunized with rLBNSE or rLBNSE-DCCp, resulting in a better protection of rLBNSE-DCBp immunized mice against the lethal challenge. Taken together, our results suggest that rRABV with G fused with DCBp is a promising rabies vaccine candidate.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.